Abstract 522P
Background
The standard treatment of relapsed small cell lung cancer (SCLC) has not been established yet, and weekly paclitaxel (PTX) is recommend as one of the treatment options for relapsed SCLC. In advanced non-small cell lung cancer, nanoparticle albumin-bound paclitaxel (nab-PTX) has shown equal activity to PTX with less neurological adverse event. However, the benefit of nab-PTX for relapsed SCLC has not been fully evaluated yet. The aim of this study is to evaluate efficacy and safety of both weekly nab-PTX and weekly PTX regimen for relapsed SCLC.
Methods
We retrospectively reviewed consecutive relapsed SCLC patients who were treated with weekly nab-PTX (80mg/m2, day1,8,15/q4 weeks) or weekly PTX (80mg/m2, day1,8,15,22/q4 weeks) at Tosei general hospital, from January 2008 to March 2019. We evaluated the objective response rate (ORR), disease control rate (DCR), progression free survival (PFS), overall survival (OS) and adverse event profile in each regimen.
Results
A total of 52 patients with relapsed SCLC were reviewed, 18 and 34 patients received weekly nab-PTX (group A) and weekly PTX (group B), respectively. Patient characteristics (group A: group B) were as follows; male 17 (94%): 28(82%), median of age 74 :70, ECOG-PS 0-1 18(100%) :29(85%), extensive disease 14(78%) :17(50%), refractory relapse 16(89%) :20(59%). ORR in group A and B were 5.6% and 8.8%, and DCR in group A and B were 55.6% and 38%, respectively. The PFS and OS had no difference between group A and B (median PFS, 3.2months and 1.7months; median OS, 5.4 months and 4.5months). Toxicity profile of group A was tolerable as well as group B. About neurological adverse event, group A had less toxicity than group B in any grade (5(28%) and 12(35%) patients) but no severe adverse event was observed.
Conclusions
Weekly nab-PTX and weekly PTX showed similar efficacy for relapsed SCLC. In terms of toxicity, weekly nab-PTX might be less toxic especially in neurological adverse event. Although this is a retrospective single center study, the nab-PTX might be a treatment option for relapsed SCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hajime Oi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
447P - Hypomagnesaemia: An unnoticed problem in lung cancer patients treated with concurrent chemoradiation
Presenter: Sharif Ahmed
Session: Poster display session
Resources:
Abstract
448P - Incidence and severity of chemotherapy induced peripheral neuropathy in geriatric population who are receiving chemotherapy
Presenter: Alekhya Mandepudi
Session: Poster display session
Resources:
Abstract
449P - Utility of screening tool for assessment of chemotherapy induced peripheral neuropathy in cancer patients
Presenter: PRUTHVI Paibhavi
Session: Poster display session
Resources:
Abstract
450P - Supportive care to control nausea and dizziness in malignant tumours: A systematic review
Presenter: Rainer Spiegel
Session: Poster display session
Resources:
Abstract
451P - The safety of ramucirumab without H1-antihistamines as a premedication in patients with solid cancers: A retrospective study
Presenter: Nobuhiro Hattori
Session: Poster display session
Resources:
Abstract
452P - Expression of erythropoietin receptor in patient with anemia related chemotherapy and its correlation with absolute reticulocyte count
Presenter: Irza Wahid
Session: Poster display session
Resources:
Abstract
453P - Body mass index did not correlate with short term overall survival in breast cancers
Presenter: Jungsun Lee
Session: Poster display session
Resources:
Abstract
454P - Predictors of severity and comparison of CTCAE V3.0 vs V4.3 in assessing chemotherapy induced extravasation injuries
Presenter: Sangana Reddy
Session: Poster display session
Resources:
Abstract
455P - Assessment of nutritional status and quality of life among cancer patients undergoing chemotherapy
Presenter: Sri Prathima
Session: Poster display session
Resources:
Abstract
456P - Use of gamma irradiated bone allografts in treatment of various bone tumours
Presenter: Anchal Mishra
Session: Poster display session
Resources:
Abstract